Chiudi menu
Group
Companies
History
Mission, Vision and Values
Business model
Innovation
Scientific research
Quality and certifications
Investor Relations
Share Capital and Shareholding
Stock performance
Stock Market Research and Studies
Brokers and SDIR
Financial statements and reports
Company profile
Presentations
Corporate Events
Euronext Milan Prospectus
Governance
Code of ethics and policies
Model 231
Intro to Special Section Model 231
Whistleblowing Reports
BOD and Committees
Statutory auditors and Audit firm
Shareholders’ Meeting
Company Documents
Internal Dealing
Sharholders Agreements
Sustainability
ESG PLAN AND SUSTAINABILITY REPORTS
SOCIAL COMMITMENT
Company Welfare
Our commitment to Sport
Careers
Media
Press releases
Press reviews
News
Chiudi ricerca
it
en
Group
Companies
History
Mission, Vision and Values
Business model
Innovation
Scientific research
Quality and certifications
Investor Relations
Share Capital and Shareholding
Stock performance
Stock Market Research and Studies
Brokers and SDIR
Financial statements and reports
Company profile
Presentations
Corporate Events
Euronext Milan Prospectus
Governance
Code of ethics and policies
Model 231
Intro to Special Section Model 231
Whistleblowing Reports
BOD and Committees
Statutory auditors and Audit firm
Shareholders’ Meeting
Company Documents
Internal Dealing
Sharholders Agreements
Sustainability
ESG PLAN AND SUSTAINABILITY REPORTS
SOCIAL COMMITMENT
Company Welfare
Our commitment to Sport
Careers
Media
Press releases
Press reviews
News
25 August 2021 |
Press
PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PATENT IN CHINA
